Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
API
0
FDF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Hydrochloride, Opipramol
2. Insidon
3. Opipramol
4. Opipramol Hydrochloride
1. 909-39-7
2. Opipramol Hydrochloride
3. Insidon
4. Opipramol Hcl
5. Opipramol Hydrochloride [usan]
6. B49obi656m
7. G-33040
8. 1-piperazineethanol, 4-(3-(5h-dibenz(b,f)azepin-5-yl)propyl)-, Dihydrochloride
9. 2-[4-(3-benzo[b][1]benzazepin-11-ylpropyl)piperazin-1-yl]ethanol;dihydrochloride
10. 4-(3-(5h-dibenz(b,f)azepin-5-yl)propyl)-1-piperazineethanol Dihydrochloride
11. 4-[3-(5h-dibenz[b,f]azepin-5-yl)propyl]-1-piperazineethanol Dihydrochloride
12. Ncgc00093619-02
13. Ensidon
14. Pramolan
15. Dsstox_cid_25752
16. Dsstox_rid_81096
17. Dsstox_gsid_45752
18. Cas-909-39-7
19. Ncgc00162068-04
20. Einecs 213-000-2
21. Unii-b49obi656m
22. Insidon (tn)
23. 4-(3-(5h-dibenzo(b,f)azepina-5-il)propil)-1-(2-idrossietil)piperazina Dicloridrato [italian]
24. 5-(gamma-(beta-hydroxyethylpiperazino)propyl)-5h-dibenzo(b,f)azepine Dihydrochloride
25. Opipramoldihydrochloride
26. Schembl366168
27. Chembl1524185
28. Dtxsid5045752
29. Opipramol Hydrochloride (jan/usan)
30. Tox21_111210
31. Tox21_113153
32. Tox21_500128
33. Opipramol Hydrochloride [jan]
34. Opipramol Dihydrochloride [mi]
35. 4-(3-(5h-dibenz(b,f)azepin-5-yl)propyl)piperazine-1-ethanol Dihydrochloride
36. Tox21_111210_1
37. Ccg-220673
38. Ccg-221432
39. Lp00128
40. Opipramol Hydrochloride [mart.]
41. 4-(3-(5h-dibenzo(b,f)azepina-5-il)propil)-1-(2-idrossietil)piperazina Dicloridrato
42. Opipramol Hydrochloride [who-dd]
43. Ncgc00093619-01
44. Ncgc00162068-06
45. Ncgc00260813-01
46. D01477
47. Opipramol Dihydrochloride, >=98% (hplc), Solid
48. Sr-01000838066
49. Sr-01000838066-3
50. Q27274351
51. (z)-2-(4-(3-(5h-dibenzo[b,f]azepin-5-yl)propyl)piperazin-1-yl)ethanol Dihydrochloride
| Molecular Weight | 436.4 g/mol |
|---|---|
| Molecular Formula | C23H31Cl2N3O |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 6 |
| Exact Mass | 435.1844180 g/mol |
| Monoisotopic Mass | 435.1844180 g/mol |
| Topological Polar Surface Area | 30 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 448 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
Adrenergic Uptake Inhibitors
Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)
Antidepressive Agents, Tricyclic
Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
ABOUT THIS PAGE
A Opipramol Dihydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Opipramol Dihydrochloride, including repackagers and relabelers. The FDA regulates Opipramol Dihydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Opipramol Dihydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Opipramol Dihydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Opipramol Dihydrochloride supplier is an individual or a company that provides Opipramol Dihydrochloride active pharmaceutical ingredient (API) or Opipramol Dihydrochloride finished formulations upon request. The Opipramol Dihydrochloride suppliers may include Opipramol Dihydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Opipramol Dihydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Opipramol Dihydrochloride written confirmation (Opipramol Dihydrochloride WC) is an official document issued by a regulatory agency to a Opipramol Dihydrochloride manufacturer, verifying that the manufacturing facility of a Opipramol Dihydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Opipramol Dihydrochloride APIs or Opipramol Dihydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Opipramol Dihydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of Opipramol Dihydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Opipramol Dihydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Opipramol Dihydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Opipramol Dihydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Opipramol Dihydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Opipramol Dihydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Opipramol Dihydrochloride suppliers with NDC on PharmaCompass.
Opipramol Dihydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Opipramol Dihydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Opipramol Dihydrochloride GMP manufacturer or Opipramol Dihydrochloride GMP API supplier for your needs.
A Opipramol Dihydrochloride CoA (Certificate of Analysis) is a formal document that attests to Opipramol Dihydrochloride's compliance with Opipramol Dihydrochloride specifications and serves as a tool for batch-level quality control.
Opipramol Dihydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Opipramol Dihydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Opipramol Dihydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Opipramol Dihydrochloride EP), Opipramol Dihydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Opipramol Dihydrochloride USP).
LOOKING FOR A SUPPLIER?
